Form 4: Acumen Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Director Jeffrey L. Ives acquired 25,000 stock options in Acumen Pharmaceuticals on June 10, 2024.
Summary
- On June 10, 2024, Jeffrey L. Ives, a director of Acumen Pharmaceuticals, acquired 25,000 stock options.
- The exercise price of these options is $2.62.
- The options vest on the earlier of June 10, 2025, or the 2025 annual stockholder meeting, contingent upon continuous service.
- The options expire on June 9, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of stock option acquisition by a director. It can be seen as slightly positive, indicating confidence, but it's not a major event.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting of the options is contingent upon the director's continuous service, suggesting a commitment to the company's future.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of transaction: Director Jeffrey L. Ives acquired stock options. |
| 06/10/2025 | Earliest vesting date for the stock options, contingent upon continuous service. |
| 06/09/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.